Entecavir Allows an Unexpectedly High Residual Replication of HBV Mutants Resistant to Lamivudine | Zendy

Andreas Geipel | Zendy; Pia L. Seiz | Zendy; Hauke Niekamp | Zendy; Maria NeumannFraune | Zendy; Ke Zhang | Zendy; Rolf Kaiser | Zendy; Ulrike Protzer | Zendy; Wolfram H. Gerlich | Zendy; Dieter Glebe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Entecavir Allows an Unexpectedly High Residual Replication of HBV Mutants Resistant to Lamivudine

Author(s) -

Andreas Geipel,

Pia L. Seiz,

Hauke Niekamp,

Maria NeumannFraune,

Ke Zhang,

Rolf Kaiser,

Ulrike Protzer,

Wolfram H. Gerlich,

Dieter Glebe

Publication year - 2014

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp2928

Subject(s) - entecavir , lamivudine , virology , hepatitis b virus , biology , reverse transcriptase , reverse transcriptase inhibitor , viral replication , drug resistance , mutant , hepatitis b , hepadnaviridae , virus , viral load , polymerase chain reaction , gene , genetics , antiretroviral therapy

Entecavir is an efficient inhibitor of HBV reverse transcriptase (RT) and widely used for therapy of chronic hepatitis B. Entecavir treatment of HBV patients with lamivudine-resistant viral strains, however, often fails, but the mechanism of cross-resistance development is not fully understood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research